Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 4/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8533461 | 0.88 | MAT2A (0.56) | MAT2AESR1KIF11KDM4EALDH1A1 | |
| SCHEMBL8515688 | 0.88 | MAT2A (0.55) | MAT2AESR1KIF11KDM4E | |
| SCHEMBL8535303 | 0.88 | MAT2A (0.55) | MAT2AKIF11 | |
| SCHEMBL8532964 | 0.86 | MAT2A (0.52) | MAT2AESR1KIF11NPC1AR | |
| SCHEMBL8538462 | 0.85 | MAT2A (0.52) | MAT2AESR1GPR84KIF11NPC1 | |
| SCHEMBL8536602 | 0.83 | MAT2A (0.62) | MAT2AKIF11KDM4EALDH1A1GLA | |
| SCHEMBL20983234 | 0.82 | MAT2A (0.58) | MAT2AESR1KDM4EALDH1A1HPGD | |
| SCHEMBL8535293 | 0.82 | MAT2A (0.48) | MAT2AESR1GPR84KIF11NPC1 | |
| SCHEMBL8532528 | 0.82 | MAT2A (0.48) | MAT2AGPR84KIF11NPC1 | |
| SCHEMBL20983225 | 0.81 | MAT2A (0.43) | MAT2AESR1GPR84ARALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10799494-B2 | Combination of respiratory electron transport chain inhibitors with a cytochrome bd inhibitor | LIVERPOOL SCHOOL TROPICAL MEDICINE (GB) | 2020-10-13 | — | — | US | claimed |
| US-20190151305-A1 | COMBINATION PRODUCT | LIVERPOOL SCHOOL TROPICAL MEDICINE (GB) | 2019-05-23 | — | — | US | claimed |
| US-10799494-B2 | Combination of respiratory electron transport chain inhibitors with a cytochrome bd inhibitor | LIVERPOOL SCHOOL TROPICAL MEDICINE (GB) | 2020-10-13 | — | — | US | disclosed |
| US-10799494-B2 | Combination of respiratory electron transport chain inhibitors with a cytochrome bd inhibitor | LIVERPOOL SCHOOL TROPICAL MEDICINE (GB) | 2020-10-13 | — | — | US | disclosed |
| US-20190151305-A1 | COMBINATION PRODUCT | LIVERPOOL SCHOOL TROPICAL MEDICINE (GB) | 2019-05-23 | — | — | US | disclosed |
| US-20190151305-A1 | COMBINATION PRODUCT | LIVERPOOL SCHOOL TROPICAL MEDICINE (GB) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10799494-B2 | Combination of respiratory electron transport chain inhibitors with a cytochrome bd inhibitor | NDUFB7, NDUFB3, NDUFB5 | MAT2A 3025/4885ESR1 4106/4885GPR84 2140/4885 |
| US-20190151305-A1 | COMBINATION PRODUCT | NDUFB5, NDUFB7, NDUFB10 | MAT2A 2903/4885ESR1 4345/4885GPR84 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.